SCHEMBL2651371

SCHEMBL2651371

O=C(O)Cc1ccccc1S(=O)(=O)C1CCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 9/20 0.50
MMP12 P39900 8/20 0.50
MMP13 P45452 8/20 0.50
MMP14 P50281 8/20 0.50
MMP9 P14780 7/20 0.50
MMP1 P03956 6/20 0.50
MMP3 P08254 6/20 0.50
MMP8 P22894 5/20 0.50
MMP16 P51512 5/20 0.50
PTGDR2 Q9Y5Y4 1/20 0.46
AKR1B1 P15121 2/20 0.44
TDP1 Q9NUW8 1/20 0.40
ALB P02768 1/20 0.40
CTSB P07858 1/20 0.40
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA3 P07451 1/20 0.37
CA4 P22748 1/20 0.37
CA6 P23280 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1014583 0.79 COMT (0.44) PTGDR2CTSBCA12CA1CA2
SCHEMBL8230938 0.79 LOXL2 (0.43) MMP13MMP1MMP8PTGDR2CTSB
SCHEMBL8254703 0.78 CTSB (0.43) MMP2MMP12MMP13MMP14MMP9
Hydrochloric Acid SCHEMBL4611724 0.78 LOXL2 (0.42) MMP13MMP1MMP8PTGDR2CTSB
Hydrochloric Acid SCHEMBL5003352 0.77 CTSB (0.42) MMP2MMP12MMP13MMP14MMP9
SCHEMBL8254111 0.76 LOXL2 (0.46) PTGDR2CTSBCA12CA1CA2
SCHEMBL1016972 0.76 CTSB (0.42) PTGDR2TDP1CTSBCA12CA1
SCHEMBL9988286 0.76 CTSB (0.42) PTGDR2CTSBCA12CA1CA2
SCHEMBL4599595 0.76 TSHR (0.51) MMP2MMP13MMP9MMP1MMP8
SCHEMBL1508334 0.74 MMP2 (0.60) MMP2MMP12MMP13MMP14MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2168962-A2 PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS Prosidion Limited (GB) 2010-03-31 EP disclosed
EP-1594867-B1 PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS PROSIDION LTD (GB) 2008-04-09 EP disclosed
US-7214681-B2 Tri(cyclo) substituted amide compounds PROSIDION LIMITED (GB) 2007-05-08 US disclosed
EP-1594867-A2 PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS Prosidion Limited (GB) 2005-11-16 EP disclosed
US-20040181067-A1 Tri(cyclo) substituted amide compounds OSI PHARMACEUTICALS, INC. 2004-09-16 US disclosed
WO-2004072031-A2 PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS PROSIDION LIMITED (GB) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040181067-A1 Tri(cyclo) substituted amide compounds GPR119, IAPP, SLC5A1 MMP2 2394/4885MMP12 4420/4885MMP13 3317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.